menu
    • menu
    [{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Croma-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Croma-Pharma \/ China National Biotech Group","highestDevelopmentStatusID":"12","companyTruncated":"Croma-Pharma \/ China National Biotech Group"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Croma-Pharma \/ Croma Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Croma-Pharma \/ Croma Pharma"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Croma-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Croma-Pharma

    Menu

    Croma-Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Lidocaine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Croma-Pharma Announces Enrollment of First Patient in Hyaluronic Acid Dermal Filler Clinical Trial in China

                            Details : Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.

                            Brand Name : Princess Volume Plus

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Hyaluronic Acid,Lidocaine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Crescita Therapeutics

                            Deal Size : $1.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®

                            Details : Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other mi...

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 28, 2021

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Crescita Therapeutics

                            Deal Size : $1.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : China National Biotech Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Croma Establishes New Joint Venture in China

                            Details : The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin produc...

                            Brand Name : Hyaluronic Acid Filler Princess

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 15, 2020

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : China National Biotech Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Croma-Pharma

                            Austria arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Croma-Pharma Announces Submission for Their Botulinum Toxin to Treat Glabellar (frown) Lines to the German Aut...

                            Details : Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.

                            Brand Name : BoNT/A-DP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 08, 2020

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth